Use of intracavernosal alprostadil in erectile dysfunction

被引：0
|
作者：
Gingell, C [1 ]
机构：
[1] Southmead Hosp, Bristol Urol Inst, Bristol B510 5NB, Avon, England
来源：
HOSPITAL MEDICINE | 1998年 / 59卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Alprostadil (prostaglandin E-1) is the most widely used, licensed vasoactive agent for intracorporeal injection in the investigation and treatment of erectile dysfunction. If hers a good side-effect profile and is effective in between 70 and 80% of patients.
引用
收藏
页码：777 / 777
页数：1
相关论文
共 50 条
  • [31] What is the current role of intracavernosal injection in management of erectile dysfunction?
    El-Sakka, A. I.
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2016, 28 (03) : 88 - 95
  • [32] Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction
    Dinsmore, W. Wallace
    Wyllie, Michael G.
    [J]. BJU INTERNATIONAL, 2008, 102 (08) : 933 - 937
  • [33] What is the current role of intracavernosal injection in management of erectile dysfunction?
    A I El-Sakka
    [J]. International Journal of Impotence Research, 2016, 28 : 88 - 95
  • [34] Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction
    Colli, E
    Calabro, A
    Gentile, V
    Mirone, V
    Soli, M
    [J]. EUROPEAN UROLOGY, 1996, 29 (01) : 59 - 62
  • [35] Treatment of erectile dysfunction with transurethral alprostadil: Effects on quality of life
    Kaiser, FE
    Weldon, K
    Gesundheit, N
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1997, 45 (09) : A33 - A33
  • [36] Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction
    Williams, G
    Abbou, CC
    Amar, ET
    Desvaux, P
    Flam, TA
    Lycklama a Nijeholt, GAB
    Lynch, SF
    Morgan, RJ
    Müller, SC
    Porst, H
    Pryor, JP
    Ryan, P
    Witzsch, UKF
    Hall, MM
    Place, VA
    Spivack, AP
    Gesundheit, N
    [J]. BRITISH JOURNAL OF UROLOGY, 1998, 81 (06): : 889 - 894
  • [37] A dose-response study of alprostadil in patients with erectile dysfunction
    Gana, TE
    Quizanos, LF
    Castell, R
    Dator, JDP
    Gatchalian, ER
    Lim, GU
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1996, 57 (09): : 700 - 710
  • [38] Thalassaemic men affected by erectile dysfunction treated with transurethral alprostadil
    Lombardo, T
    Giammusso, B
    Frontini, V
    D'Arpa, S
    Pafumi, C
    Caruso, S
    [J]. HUMAN REPRODUCTION, 2000, 15 (11) : 2375 - 2378
  • [39] Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience
    Cuzin, Beatrice
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (04) : 249 - 256
  • [40] COMPARING ERECTILE DYSFUNCTION (ED) OUTCOMES FOLLOWING PRIAPISM AS AN ADVERSE EFFECT OF INTRACAVERNOSAL INJECTABLE MEDICATIONS TO PRIAPISM DUE TO RECREATIONAL USE OF INTRACAVERNOSAL INJECTABLE
    Masterson, J.
    Choi, E.
    Zhao, H.
    Kim, H.
    Anger, J.
    [J]. JOURNAL OF SEXUAL MEDICINE, 2023, 20
12345